Tenaya SVP Higa granted RSUs and 175,500 options

Tenaya Therapeutics, Inc. granted new equity awards to SVP, Finance Tomohiro Higa.

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. granted new equity awards to SVP, Finance Tomohiro Higa. On February 3, 2026, he received 29,250 shares of common stock in the form of restricted stock units, issued at $0 and bringing his directly held common stock (including unvested RSUs) to 123,221 shares.

Higa also received a stock option for 175,500 shares of common stock with an exercise price of $0.915 per share, expiring on February 2, 2036. The option vests in equal monthly installments over 48 months starting one month after the grant date, while the new RSUs vest in eight equal installments every six months beginning August 15, 2026.

Insider Trade Summary

Grant/Award: 204,750 shares

Grant/Award 2 txns

Insider Higa Tomohiro

Role SVP, Finance

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	175,500	$0.00	$0.00
Grant/Award	Common Stock	29,250	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 175,500 contracts (Direct); Common Stock — 123,221 shares (Direct)

Footnotes (4)

1. F1. Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.
2. F2. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.
3. F3. Includes 79,720 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
4. F4. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Tenaya Therapeutics (TNYA) grant to Tomohiro Higa?

Tenaya Therapeutics granted Tomohiro Higa 29,250 restricted stock units of common stock and a stock option for 175,500 shares with an exercise price of $0.915 per share, all under the company’s 2021 Equity Incentive Plan.

How do the new RSUs for TNYA executive Tomohiro Higa vest?

The 29,250 RSUs granted to Tomohiro Higa vest over four years. One-eighth vests on August 15, 2026, and an additional one-eighth vests every six months thereafter until the award is fully vested, assuming continued service.

What is the vesting schedule for Tomohiro Higa’s 175,500 TNYA stock options?

The 175,500 stock options vest in 48 equal monthly installments. Vesting starts on the one-month anniversary of the February 3, 2026 grant date and continues monthly until fully vested, with an expiration date of February 2, 2036.

What is Tomohiro Higa’s total TNYA common stock ownership after this Form 4?

After these grants, Tomohiro Higa beneficially owns 123,221 shares of Tenaya Therapeutics common stock directly, including 79,720 shares that will be issued upon vesting of previously granted restricted stock units, plus separate options for 175,500 shares.

At what price can Tomohiro Higa exercise his new Tenaya Therapeutics stock options?

Tomohiro Higa’s newly granted stock option allows him to purchase 175,500 Tenaya Therapeutics shares at an exercise price of $0.915 per share. The option was granted on February 3, 2026 and remains exercisable until its February 2, 2036 expiration.

Are Tomohiro Higa’s new Tenaya Therapeutics awards direct or indirect holdings?

Both the 29,250 RSUs and the 175,500 stock options are reported as held directly by Tomohiro Higa. The filing does not indicate any indirect ownership through entities or family members for these specific awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 06:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higa Tomohiro

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/03/2026(2)		A		29,250	A	$0	123,221(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.915	02/03/2026		A		175,500		03/03/2026(4)	02/02/2036	Common Stock	175,500	$0	175,500	D

Explanation of Responses:

1. Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

2. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

3. Includes 79,720 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

4. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

	/s/ Jennifer Drimmer Rokovich, Attorney in Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.